Most Read Articles
09 Dec 2016
All patients with acne are potentially at risk of scarring. Professor Goh Chee Leok addresses this issue by focussing on preventing the development of scars in his talk at the 41st Annual Meeting of the Dermatological Society of Malaysia held in Kuching, Sarawak.
01 Jun 2016
Adapalene 0.3%/benzoyl peroxide 2.5% topical gel is a safe and effective treatment option in patients with moderate and severe inflammatory non-nodulocystic acne, based on a multicentre, randomised, double-blind, parallel-group study.
06 Jun 2016

The recent Paediatrics in Practice (PIP) 2016 held recently in Selangor was a success. On top of the launch of a locally published atlas, the conference also featured the introduction of DEBRA (Dystrophic Epidermolysis Bullosa Research Association), various presentations, a workshop and panel discussion on paediatric skin diseases by prominent specialists such as Dr. Tang Jyh Jong, Dr. Tan Wooi Chiang, Dr. Chan Lee Chin, Dr. Sabeera Begum and Dr. Leong Kin Fon. MIMS Doctor spoke to Dr. Thiyagar Nadarajaw, paediatrician and adolescent medicine specialist and Leong, a consultant paediatric dermatologist at the Kuala Lumpur Hospital about the PIP workshop and their thoughts on the atlas.

26 May 2016
Melasma is a benign pigmentary skin disorder. However, it features prominently on sun-exposed areas, typically the face and arms, and as such affects the quality of life of those with the disorder. Radha Chitale spoke with Dr. Gavin Ong Chun Wei, a dermatologist at The Skin Specialist clinic in Singapore, about how GPs can best diagnose and treat patients with melasma.

Clinical benefit with immune checkpoint inhibitors in advanced melanoma

Elaine Tan
20 Oct 2016

Data from trials presented at the European Society for Medical Oncology (ESMO) Congress 2016 showed clinically significant overall survival (OS) benefit with CTLA-4 and PD-1 inhibitors in patients with advanced melanoma.

“CA184-169 is the first phase III study directly comparing the benefit-risk profile of ipilimumab 10 mg/kg vs 3 mg/kg in patients [n=727] with untreated or previously treated unresectable stage III/IV melanoma who had not received prior BRAF or immune checkpoint inhibitors. Results showed improved OS with higher-dose ipilimumab,” reported lead investigator Dr Paolo Ascierto of the Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy. [ESMO 2016, abstract 1106O]

 At a minimum follow-up of 43 months, median OS (primary endpoint) was 15.7 months in the 10 mg/kg arm vs 11.5 months in the 3 mg/kg arm (hazard ratio [HR], 0.84; p=0.04).  However, patients who received higher-dose ipilimumab experienced higher rates of treatment-related grade 3–5 adverse events (AEs) (34.3 vs 18.5 percent), AEs leading to discontinuation, and treatment- and immune-related AEs.  

“Although the treatment landscape has evolved for first-line melanoma treatment, the clinical utility of ipilimumab in refractory patients warrants further evaluation,” Ascierto concluded.

“These results suggest that there is more to gain from CTLA-4 blockade at 3 mg/kg [than 10 mg/kg]. However, first-line ipilimumab is no longer a standard in treating melanoma and has been replaced by PD-1 or PD-1/CTLA-4 blockade,” said discussant Dr Oliver Michelin of the Swiss Institute of Bioinformatics, Lausanne, Switzerland.

The KEYNOTE-002 trial demonstrated superior progression-free survival with the PD-1 inhibitor pembrolizumab vs investigator-choice chemotherapy in patients with advanced, ipilimumab-refractory melanoma. However, OS was not significant different between the two arms. [ESMO 2016, abstract 1107O]

“Nevertheless, PD-1 inhibitors are effective and well tolerated in first-, second- and subsequent lines of treatment, and are therefore an important component of our armament,” said Michelin. “Results from the CA184-169 study also suggest that we should keep a close eye on CTLA-4 blockade and long-term benefit when designing the next-generation combination therapy.”

Editor's Recommendations
Most Read Articles
09 Dec 2016
All patients with acne are potentially at risk of scarring. Professor Goh Chee Leok addresses this issue by focussing on preventing the development of scars in his talk at the 41st Annual Meeting of the Dermatological Society of Malaysia held in Kuching, Sarawak.
01 Jun 2016
Adapalene 0.3%/benzoyl peroxide 2.5% topical gel is a safe and effective treatment option in patients with moderate and severe inflammatory non-nodulocystic acne, based on a multicentre, randomised, double-blind, parallel-group study.
06 Jun 2016

The recent Paediatrics in Practice (PIP) 2016 held recently in Selangor was a success. On top of the launch of a locally published atlas, the conference also featured the introduction of DEBRA (Dystrophic Epidermolysis Bullosa Research Association), various presentations, a workshop and panel discussion on paediatric skin diseases by prominent specialists such as Dr. Tang Jyh Jong, Dr. Tan Wooi Chiang, Dr. Chan Lee Chin, Dr. Sabeera Begum and Dr. Leong Kin Fon. MIMS Doctor spoke to Dr. Thiyagar Nadarajaw, paediatrician and adolescent medicine specialist and Leong, a consultant paediatric dermatologist at the Kuala Lumpur Hospital about the PIP workshop and their thoughts on the atlas.

26 May 2016
Melasma is a benign pigmentary skin disorder. However, it features prominently on sun-exposed areas, typically the face and arms, and as such affects the quality of life of those with the disorder. Radha Chitale spoke with Dr. Gavin Ong Chun Wei, a dermatologist at The Skin Specialist clinic in Singapore, about how GPs can best diagnose and treat patients with melasma.